Sector: Healthcare | Industry: Pharmaceuticals |
Company Contact | |
Address: | Dome Tower 800, 333 7 Ave. S.W. CALGARY AB T2P 2Z1 |
Tel: | N/A |
Website: | https://voyageurpharmaceuticals.ca |
IR: | See website |
Key People | ||
Brent Willis President, Chief Executive Officer, Director | Albert Deslauriers Chief Financial Officer | Bradly Willis Chief Operating Officer, Director |
Business Overview |
Voyageur Pharmaceuticals Ltd. is a Canadian company, which develops barium, iodine and carbon active pharmaceutical ingredients. The Company is focused on producing its own barium, iodine and fullerene minerals. The Company, through its subsidiaries, Voyageur Industrial Minerals Ltd. and Voyageur Minerals Inc., is engaged in acquiring, exploring and developing raw materials for pharmaceutical products, primarily in the province of British Columbia, Canada and the state of Utah, United States. Its properties include Jubilee Mountain, Falcon and Paradox Basin. It owns a 100% interest in two barium sulphate (barite) projects, including the Frances Creek and Pedley Mountain property. It holds interests in a high-grade iodine, lithium, and bromine brine project situated in Utah, United States. It owns a 100% interest in two battery mineral projects that is focused on copper/zinc development. Its pipeline products include SmoothX 2.0%, MultiX Thick, MultiX Thin, HDX, LDX, VY-101 and VY-103. |
Financial Overview |
For the fiscal year ended 30 November 2023, Voyageur Pharmaceuticals Ltd revenues was not reported. Net loss decreased 20% to C$1.4M. Lower net loss reflects Market and product development decrease of 47% to C$281K (expense), General and administrative decrease of 42% to C$149K (expense), Wages and benefits decrease of 20% to C$330K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -C$0.02 to -C$0.01. |
Reporting Currency: | Canadian Dollars |
Enterprise value: | $7.70M as of Nov 30, 2023 |
Annual revenue (TTM): | $0.00M as of Nov 30, 2023 |
EBITDA (TTM): | -$1.34M as of Nov 30, 2023 |
Net annual income (TTM): | -$1.40M as of Nov 30, 2023 |
Free cash flow (TTM): | -$1.17M as of Nov 30, 2023 |
Net Debt Last Fiscal Year: | $0.04M as of Nov 30, 2023 |
Shares outstanding: | 138,881,576 as of Mar 13, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |